ClearPoint Neuro, Inc. (CLPT) - רווח נקי למניה (EPS TTM)

ClearPoint Neuro, Inc. (CLPT) maintains an impeccable reputation in precision neurosurgery by implementing high-precision robotic stereotactic systems. The increasing number of gene therapy trials is driving demand for MRI navigation, which is supported by the rolling annual earnings per share. The current level of financial stability determines the -1.22 metric, allowing for an assessment of the business's margin of safety during a period of expensive borrowing.

ClearPoint Neuro, Inc. (CLPT) maintains a monopoly status in the neuronavigation segment, allowing the company to exercise pricing power and directly impact overall business profitability. The company's net income per share over 12 months is calculated by dividing total net income by the number of securities, reflecting the actual per-unit earnings of the assets and helping investors assess the issuer's fundamental stability during periods of market consolidation.